Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental combo for tough blood cancers hits early snag

NCT ID NCT04702425

Terminated Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-stage trial tested a combination of two experimental drugs, VOB560 and MIK665, in 37 people with relapsed or refractory non-Hodgkin lymphoma, acute myeloid leukemia, or multiple myeloma. The drugs aim to block proteins that help cancer cells survive, forcing them to die. The study was terminated early, so results on safety and effectiveness are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
VOB560 and MIK665 (two experimental drugs that block proteins protecting cancer cells)
What this could lead to
If it works, this combination could offer a new treatment option for people with blood cancers that have stopped responding to standard therapies.
What could go wrong
This was a very early (phase 1) trial that was terminated, so we don't know if the combination is safe or effective. The drugs may cause serious side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia non-Hodgkin lymphoma plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA (AML) MULTIPLE MYELOMA (MM) NON HODGKIN LYMPHOMA (NHL)

Contacts and locations

Locations

  • Novartis Investigative Site

    Ghent, 9000, Belgium

  • Novartis Investigative Site

    HUS, FIN-00029, Finland

  • Novartis Investigative Site

    Hong Kong, Hong Kong

  • Novartis Investigative Site

    Tel Aviv, 6423906, Israel

  • Novartis Investigative Site

    Rozzano, MI, 20089, Italy

  • Novartis Investigative Site

    Sunto Gun, Shizuoka, 411 8777, Japan

  • Novartis Investigative Site

    Seoul, 03080, South Korea

  • Novartis Investigative Site

    Santander, Cantabria, 39008, Spain

  • Uni of TX MD Anderson Cancer Cntr UT MD Anderson Cancer Ctr

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.